DDRE-17. INITIAL CLINICAL EXPERIENCE USING OSIMERTINIB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH EGFR ALTERATIONS

EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target. Unlike other EGFR tyrosine kinase inhibitors (TKIs), osimertinib (osi), a third-generation, irreversible EGFR-TKI commonly used to treat EGFR-mutant lung c...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Abousaud, Marin, Faroqui, Naqeeb, Hsu, Fang-Chi, Lesser, Glenn, Strowd, Roy, Ramkissoon, Shakti, Kwatra, Madan, Houston, Kristin Strickland, Carter, Annette, DeTroye, Alisha
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Drug Discovery, Drug Resistance
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651426/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.262
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk